Today: 19 July 2026
Browse Category

EPA:SAN 30 August 2025 - 6 November 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax, Inc. reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion. Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance. ir.novavax.com
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org.
Go toTop